BAKER BROS. ADVISORS LP

Q4 2024 13F Holdings

  • Location
    new york, NY
  • Num holdings

    95

  • Value ($000)

    $9,361,492

  • Date Filed
    02/14/2025
  • Form type
    13F-HR
  • CIK
    0001263508
  • All SEC filings
  • Note
    Holdings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q4 2024 to
Select Quarter
Issuer Name
Class
CUSIP
VALUE
%
Shares
Principal
Option Type
INCY
INCY

Incyte Corporation

COM
45337C102
$2.12B
23 %

30,739,466

BGNE
BGNE

BeiGene, Ltd.

SPONSORED ADR
07725L102
$1.76B
19 %

9,531,880

ACAD
ACAD

ACADIA Pharmaceuticals Inc.

COM
004225108
$786.81M
8 %

42,877,916

MDGL
MDGL

Madrigal Pharmaceuticals, Inc.

COM
558868105
$609.30M
7 %

1,974,590

SMMT
SMMT

Summit Therapeutics Inc.

COM
86627T108
$435.86M
5 %

24,424,865

RVMD
RVMD

Revolution Medicines, Inc.

COM
76155X100
$347.16M
4 %

7,936,972

INSM
INSM

Insmed Incorporated

COM PAR $.01
457669307
$345.67M
4 %

5,006,863

RYTM
RYTM

Rhythm Pharmaceuticals, Inc.

COM
76243J105
$340.60M
4 %

6,084,249

KYMR
KYMR

Kymera Therapeutics, Inc.

COM
501575104
$241.22M
3 %

5,995,929

KOD
KOD

Kodiak Sciences Inc.

COM
50015M109
$172.24M
2 %

17,310,490

Rows Per Page
10
  • 10
  • 50
  • 100
1 - 10 of 95